NDC Compounded Drug 69194-802-01 Lidocaine Hydrochloride; Oxymetazoline Hydrochloride

Solution Nasal

Compounded Drug Product Information

NDC Product Code 69194-802
NDC Package Code 69194-802-01
11-Digit NDC Billing Format NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
69194080201
Package Description 2 mL in 1 SYRINGE
Product Type What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Human Compounded Drug
Proprietary Name What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
802 Lidocaine Hcl 2%, Oxymetazoline Hcl 0.025% Syringe
Non-Proprietary Name What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
Lidocaine Hcl, Oxymetazoline Hcl
Substance Name What is the Substance Name?
An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
Lidocaine Hydrochloride; Oxymetazoline Hydrochloride
Dosage Form Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Route Name Nasal - Administration to the nose; administered by way of the nose.
Marketing Category OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Code 69194
Labeler Name What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.
Pine Pharmaceuticals Llc
Substance Name Lidocaine Hydrochloride; Oxymetazoline Hydrochloride
Active Ingredients Information 20 mg/1 mL; .25 mg/1 mL
Reporting Period 2024-2

Frequently Asked Questions

What is the NDC number assigned to 802 Lidocaine Hcl 2%, Oxymetazoline Hcl 0.025% Syringe?

802 Lidocaine Hcl 2%, Oxymetazoline Hcl 0.025% Syringe was assigned by its manufacturer with NDC product code 69194-802. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.

Which are the NDC package codes for 802 Lidocaine Hcl 2%, Oxymetazoline Hcl 0.025% Syringe?

The NDC package code 69194-802-01 was assigned to a 2 mL in 1 SYRINGE of lidocaine hydrochloride; oxymetazoline hydrochloride administered nasal via solution.

Who manufactures this product?

802 Lidocaine Hcl 2%, Oxymetazoline Hcl 0.025% Syringe is manufactured by an outsourced facility and labeled by Pine Pharmaceuticals Llc. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.